+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 86 Actively Recruiting clinical trials

P

Actively Recruiting

The LuDO-N Trial is a phase II multi-center clinical study investigating the use of 177Lu-DOTATATE in children with recurrent or relapsed high-risk neuroblastoma. This trial aims to assess how well this treatment works by measuring the response at 1 and 4 months after treatment ends. Secondary goals include evaluating survival rates, treatment-related side effects, and examining how tumor characteristics relate to treatment response. Participants receive two doses of 177Lu-DOTATATE administered intravenously, with at least two weeks between doses. The first dose is based on the patients weight, while the second dose is adjusted using scans to control radiation exposure, particularly to avoid kidney toxicity. Patients must be prepared for autologous stem cell transplantation as part of this intensified treatment approach. During the study, participants will undergo various scans and laboratory tests before starting treatment and at scheduled times to monitor tumor response and side effects. Researchers will assess treatment effectiveness using established neuroblastoma response criteria and will follow patients for up to five years to monitor survival and any long-term effects. The total participation time includes treatment administration and extended follow-up for safety and outcomes.

Age: 18Months +All GendersPhase 2
5 locations
T

Actively Recruiting

Healthy Volunteer

Researchers are evaluating CPV-104, a new medicine designed to regulate the complement system, which may be overactive in C3 glomerulopathy C3G, an ultra-rare kidney disorder. This phase 1 trial is the first time CPV-104 is tested in humans, including both healthy adults and adults with C3G. The study aims to assess safety, tolerability, how the body processes the medicine, and immune system reactions. The trial has two parts Part 1 involves healthy volunteers receiving a single intravenous dose of CPV-104 or placebo in a randomized, double-blind setting. Part 2 involves patients with C3G receiving four weekly intravenous doses of CPV-104 without placebo. Dose escalation depends on safety reviews. All treatments are given by healthcare professionals. Participants will be closely monitored through side-effect checks, blood and urine tests, ECGs, vital signs, and blood samples to measure drug levels and antibodies. For C3G patients, kidney function will also be observed. Safety Review Committee regularly reviews data to ensure participant safety. The study measures severe and serious adverse drug reactions up to 29 days for healthy volunteers and up to 50 days for C3G patients.

Age: 18Years +All GendersPhase 1
17 locations
C

Actively Recruiting

Researchers are evaluating different arthroscopic meniscus repair methods for young patients with traumatic meniscal tears. This study compares the outcomes of a standard meniscus suturing technique with a technique that includes an additional fibrin clot approach, aiming to understand how these tools affect meniscus recovery after repair. The trial involves patients under 19 years old with traumatic isolated full-thickness meniscal tears. The study randomly assigns participants into two groups one undergoes the conventional arthroscopic meniscus repair, and the other receives meniscus repair with fibrin clot augmentation. The fibrin clot is prepared from the patients blood and placed carefully into the meniscus during surgery to potentially enhance healing. Both groups are monitored over a long term to compare their recovery. Participants are assessed before treatment and then at 12 and 24 months after surgery using knee function questionnaires like the Pediatric International Documentation Committee Subjective Knee Form, Lysholm knee scale, and pediatric quality of life surveys. Clinical evaluations focus on pain, swelling, knee motion, and MRI imaging to track healing. Revision surgery rates are also recorded to measure treatment success during follow-up.

Age: 0Years - 19YearsAll GendersPhase Not Applicable
2 locations
E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a mentalization-based prevention program aimed at improving well-being and mental health in children aged 8 to 10 years and their families across four European countries Germany, Lithuania, Spain, and Switzerland. The study is designed as a partially randomized controlled trial and investigates how multi-level interventions involving children, parents, and teachers can promote mental health, reduce stigma, enhance help-seeking behavior, and improve classroom climate and parenting skills. The program includes a universal prevention workshop delivered at schools for all children, focusing on mental health awareness and peer support skills. Parents receive one of two different intervention trainings or a parenting guidebook one group attends 10 weekly sessions of the Lighthouse Program targeting secure attachment and reflective parenting behaviors, and another group participates in 6 bi-weekly Mentalization Based Skills Training sessions focusing on attentional control and emotion regulation. An active control group receives a parenting guidebook, while a passive control group participates in follow-up assessments without intervention. Participants will be involved in data collection at multiple time points baseline, post-intervention at 3 months, and follow-ups at 6 and 12 months. Assessments include questionnaires measuring childrens and parents well-being and mental health, parental efficacy and stress, classroom climate, teaching efficacy, and mental health stigma. Focus groups after the post-assessment will gather feedback on implementation and satisfaction. The study aims to follow 5,000 children, their parents, and teachers over a year to evaluate long-term program effects.

Age: 8Years +All GendersPhase Not Applicable
4 locations
P

Actively Recruiting

Researchers are evaluating etelcalcetide for treating secondary hyperparathyroidism SHPT in children and adolescents aged 2 to under 18 years who have chronic kidney disease CKD and are on hemodialysis. This phase 3, single-arm, open-label study aims to assess the drugs efficacy, safety, pharmacokinetics, and pharmacodynamics. SHPT is a common complication in CKD patients on dialysis, and etelcalcetide has been approved for adults but is being studied in pediatric patients here. Participants will receive etelcalcetide alongside their standard care. The treatment involves multiple doses with titration tailored to each participant. The study includes regular monitoring during the treatment period, which can last up to 31 weeks. The drugs effects on parathyroid hormone levels, calcium, phosphorus, and other blood markers will be evaluated. Pharmacokinetic measures will track etelcalcetide concentrations before and after dialysis. Throughout the study, participants undergo laboratory tests including iPTH, serum calcium, phosphorus levels, and electrocardiograms. Safety is monitored by recording any adverse events. The primary outcome focuses on the percent change in iPTH between weeks 20 and 26. Secondary outcomes include reductions in iPTH, calcium and phosphorus levels, and hypocalcemia incidence. The trial concludes with assessments up to week 31, and participants adherence to treatment and visit schedules is closely followed.

Age: 2Years - 17YearsAll GendersPhase 3
23 locations
E

Actively Recruiting

This research aims to evaluate the safety and feasibility of a new paddle-shaped, high-density, multi-electrode catheter designed for mapping the atrial and ventricular regions of the heart in patients with various types of cardiac arrhythmias. The study includes adults diagnosed with arrhythmias such as ventricular tachycardia, atrial fibrillation, atrial tachycardia, and premature ventricular contraction who are scheduled for clinically indicated mapping and ablation procedures. Participants will undergo mapping using the investigational catheter during their planned ablation procedure. The catheter is used solely for mapping and not for treatment. The study observes the completion of all required mapping steps before ablation and any additional clinically necessary mapping. The investigational catheter is evaluated for deployment, visualization, maneuverability, and signal quality during the procedure. During the study, participants will be monitored for serious and non-serious adverse events related to the catheter for up to seven days after the procedure. Researchers will assess the safety of the device and whether pre-ablation mapping requirements are met. Participants will undergo standard clinical care alongside study assessments, with follow-up evaluations focusing on safety and device performance shortly after the mapping procedure.

Age: 18Years +All GendersPhase Not Applicable
5 locations
P

Actively Recruiting

Researchers are evaluating calderasib alone and in combination with other therapies for people with advanced solid tumors that have a specific KRAS G12C mutation. The study is designed to assess the safety, how the body processes the drug pharmacokinetics, and the effectiveness of calderasib and its combinations. Participants have advanced cancers confirmed by specific tests and have often received prior treatments. Participants are assigned to one of several groups receiving different treatments. Some receive daily oral doses of calderasib alone with doses increasing up to 800 mg, adjusted as needed for safety. Others receive calderasib combined with pembrolizumab infusions every 21 days for up to 35 cycles 24 months, sometimes with additional chemotherapy drugs like carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, or 5-fluorouracil according to standard dosing schedules. Treatments continue until the disease progresses or participants stop. During the study, participants have regular visits for drug dosing and safety monitoring. Researchers track side effects, dose-limiting toxicities, and treatment discontinuations over months. Blood samples are taken at specific times to measure drug levels and how the body absorbs and clears calderasib. The main outcomes include safety measures up to about 56 months and response rates. This long study period helps understand how participants respond and tolerate the treatments over time.

Age: 18Years +All GendersPhase 1
75 locations
E

Actively Recruiting

Researchers are evaluating intravenous efgartigimod in children and adolescents aged 12 to under 18 years who have chronic immune thrombocytopenia ITP. The study aims to confirm the correct dose of efgartigimod and compare it to a placebo during a double-blinded treatment period. This trial is part of a Phase 2 and 3 study sponsored by argenx to improve treatment options for pediatric patients with chronic ITP. Participants are randomly assigned in a 21 ratio to receive either efgartigimod IV or placebo IV for up to 24 weeks during the double-blinded treatment period. After this, all participants receive efgartigimod IV during an open-label treatment period lasting up to one year. Participants may continue for a second year of open-label treatment followed by an approximately 8-week follow-up period without the study drug. Total participation can last up to 138 weeks. During the study, participants have regular assessments including blood tests to measure efgartigimod levels and total IgG, platelet counts, and bleeding scores. Researchers also monitor adverse events and changes in quality of life through questionnaires. These evaluations occur throughout the treatment and follow-up periods to understand drug effects, safety, and disease control in this pediatric population.

Age: 12Years - 17YearsAll GendersPhase 2Phase 3
26 locations
E

Actively Recruiting

Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.

Age: 18Years +All GendersPhase 3
182 locations

1-10 of 86

1